Collectively, these studies indicate that Wnt5a can enhance resistance of ROR1Hi CLL cells to venetoclax by increasing BCL-XL expression, and that this effect could be inhibited by this anti-ROR1 mAb. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.